Jazz Pharma acquires narcolepsy drug

Jazz Pharmaceuticals (JAZZ -1.3%) has acquired the narcolepsy treatment ADX-N05 from Aerial BioPharma.

JAZZ is paying $125M upfront and Aerial, as well as SK Biopharmaceuticals (which has commercial rights in certain Asian countries) are eligible for milestone payments and tiered royalties on any eventual sales.

JAZZ CEO Bruce Cozadd calls the drug "a strong fit with [the company's] specialty focus." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs